Transplantation in chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Chronic lymphocytic leukemia (CLL) lacks curative treatment options beyond stem cell transplantation (SCT).
• Both autologous and allogeneic SCT are being investigated for CLL, with feasibility demonstrated in clinical trials.
• Current data indicate autologous SCT is not curative, and myeloablative SCT carries high treatment-related mortality.

Purpose of the Study:

• To explore the role and outcomes of stem cell transplantation (SCT) in chronic lymphocytic leukemia (CLL).
• To evaluate the feasibility and effectiveness of autologous and allogeneic SCT in CLL patients.
• To assess the potential of SCT, particularly reduced-intensity conditioning, in improving survival for CLL.

Main Methods:

• Review of clinical trials investigating autologous and allogeneic SCT in CLL.
• Analysis of treatment-related mortality and curative potential of different SCT approaches.
• Evaluation of the graft-versus-leukemia effect in CLL patients undergoing SCT.

Main Results:

• Autologous SCT has not proven curative for CLL.
• Myeloablative SCT offers potential cure but is linked to significant treatment-related mortality.
• Reduced-intensity conditioning SCT demonstrates a graft-versus-leukemia effect with encouraging outcomes in CLL.

Conclusions:

• SCT, especially reduced-intensity conditioning, shows promise for younger, poor-risk CLL patients due to a demonstrated graft-versus-leukemia effect.
• SCT may represent a treatment of choice for select CLL patients, given the lack of survival-improving alternatives.
• Continued enrollment in well-designed clinical trials is crucial to compare SCT advancements with chemoimmunotherapy in CLL.